FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______ TO _______ Securities registered pursuant to Section 12(b) of the Act: | Title of each class | Trading symbol(s) | Name of each exchange on which registered | | --- | --- ...

Financial Performance - The Company incurred a net loss of approximately $5.6 million in 2024, with an accumulated deficit of approximately $277 million as of December 31, 2024[146]. - The Company's quarterly and annual operating and financial results are likely to fluctuate significantly due to various external factors[147]. - The Company expects its cash and cash equivalents of $17.2 million as of December 31, 2024, to fund operations for at least the next twelve months[148]. - The company reported goodwill of $8.4 million as of December 31, 2024, which is subject to impairment assessments that could adversely affect future earnings[172]. - Approximately 14% of the Company's revenue for the fiscal year ended 2024 was derived from customers outside of the U.S., primarily in Europe[182]. - The company sold 1,057,814 shares of its common stock at a weighted average price of $2.18 per share, resulting in cash proceeds of $2.0 million for the year ended December 31, 2023[243]. Revenue and Market Risks - The Company has paused U.S. sales of its ProFound AI® Risk product pending FDA regulatory clearance, which may impact future revenue[152]. - The markets for the Company's products may not develop as expected, leading to barriers in achieving broad market acceptance[156]. - The Company relies on a limited number of customers for a significant portion of its total revenue, making it vulnerable to the loss of key clients[146]. - The company's revenue from OEM partners accounted for 26% of total revenue in 2024, with GE Healthcare contributing 17%[170]. - The market for full field digital mammography systems and related products is crucial for the company's future growth, but may not develop as anticipated due to economic conditions and reimbursement issues[169]. - The healthcare industry consolidation could reduce the Company's potential customer base and demand for its systems, impacting revenue generation[188]. Operational and Compliance Risks - The Company faces legal, business, and operational risks associated with the use of AI and machine learning technologies in its offerings[146]. - The Company may be exposed to significant product liability claims, which could harm its reputation and financial condition[160]. - The Company must comply with Nasdaq's continued listing requirements, including maintaining a minimum closing bid price of $1.00 per share[196]. - The healthcare industry is subject to extensive regulation, and non-compliance could result in significant costs, including fines and exclusion from government healthcare programs[205]. - The Company’s CAD systems are classified as medical devices and are subject to extensive FDA regulation, which includes manufacturing operations and product labeling[214]. - Regulatory changes or challenges could adversely affect the Company’s ability to commercialize existing and future products, impacting revenue generation[212]. - The Company may face substantial costs related to compliance with evolving privacy and data protection laws, including HIPAA[226]. - The Company’s operations are subject to audits and investigations from government agencies, which could disrupt business and lead to significant defense costs[209]. - The Company may incur substantial expenses if claims arise regarding the wrongful use or disclosure of confidential information by its employees[187]. - Compliance with healthcare fraud and abuse laws could restrict the Company’s sales and marketing practices, leading to potential legal and financial repercussions[211]. Strategic and Developmental Challenges - The Company is transitioning to a software as a service (SaaS) model, which may impact revenue recognition and cash flow[141]. - The Company is transitioning to a subscription licensing model, which may lead to unpredictable revenue due to limited operating history with this model[171]. - The Company is developing a new product in collaboration with Solis to detect BAC using mammography, but regulatory approval and market acceptance are uncertain[164]. - The Company’s ability to adapt to evolving technologies is critical, as failure to do so may render its products obsolete and negatively impact business[176]. - Clinical trials are expensive and lengthy, with uncertain outcomes that could delay regulatory approvals and revenue generation[189]. - Strategic transactions, such as acquisitions or joint ventures, could disrupt operations and may not yield the anticipated benefits[220]. Financial and Market Conditions - The Company may need to seek additional capital sooner than planned to fund product development and commercialization[149]. - The Company may experience fluctuations in its effective tax rate due to various factors, including changes in geographic earnings mix and tax law changes[173]. - The Company is exposed to competitive pressures from larger firms with greater resources, which could adversely affect its market position[178]. - Changes in credit ratings could lead to increased borrowing costs and limit financing options, potentially affecting the Company's operational flexibility[253]. - Unfavorable global economic conditions, including geopolitical events and inflationary pressures, could weaken demand for the Company's products and impact capital raising efforts[254]. - The Trump administration's proposed tariffs on imports from various countries could significantly affect the U.S. healthcare industry, with potential downstream impacts on the Company[255]. Cybersecurity and Data Protection - The Company faces risks related to cybersecurity incidents that could compromise customer data and result in significant liabilities[247]. - The Company may face significant capital expenditures to protect against security breaches and hackers due to vulnerabilities in its infrastructure and systems[180]. - The European Union's General Data Protection Regulation (GDPR) imposes penalties of up to 4% of worldwide revenue for non-compliance[234]. - The EU AI Act, published in 2024, may impose fines of up to 7% of worldwide annual turnover for breaches related to AI regulations[232]. - The Company is subject to complex regulations regarding AI and machine learning, which may require operational changes and increase costs[232]. Management and Governance - The Company underwent management changes, including the Chief Executive Officer and Chief Financial Officer, during the year ended December 31, 2023[192]. - The Company is classified as a "smaller reporting company," which may make its stock less attractive to investors due to reduced disclosure requirements[244]. - Future issuances of common stock may cause significant dilution of existing shareholders' equity interests[242]. - The Company has the ability to issue up to 1,000,000 shares of preferred stock, which could affect existing stockholders' rights[237]. - The Company's stock price has experienced volatility, which may impair its ability to finance strategic transactions[240]. - The Company is required to assess the effectiveness of its internal controls over financial reporting as per Section 404 of the Sarbanes-Oxley Act, dedicating significant resources for compliance for the year ended December 31, 2024[252].

OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________ OR ☐ SHELL COMPANY REPORT PURSUANT TO S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) Registrant's telephone number, including area code: (617) 334-2805 Securities registered pursuant to Section 12(b) of the Act: | | | Name of each exchange on | | --- | --- | --- | | Title of each class | Trading Symbol(s) | which registered | | Units, each consisting of one Class A | NTWOU | The Nasdaq Stock Market LLC | | Ordinary Share and one-half of one | | | | Redeemable Warrant | | | | Class A Ordinary Shares, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organ ...

Exhibit 99.1 Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) ("Glucotrack" or the "Company"), a medical technology company focused on the design, development, and commercialization ...

Exhibit 99.1 Maui Land & Pineapple Company Reports Fiscal 2024 Results KAPALUA, Hawai'i / March 31, 2025 (BusinessWire) – Maui Land & Pineapple Company, Inc. (NYSE: MLP) today reported financial results covering the year ended December 31, 2024 and announced the date and time of their Annual Meeting of Stockholders, which will be held virtually on Wednesday, May 21, 2025, at 8:30 a.m., Hawai'i Standard Time, via conference call. "In 2024, our team made significant strides in implementing a strategic plan to ...

Business Operations and Strategy - Spruce Power operates approximately 85,000 home solar assets and customer contracts, generating revenues primarily through long-term customer agreements and third-party contracts for solar renewable energy credits[18]. - The company completed the acquisition of approximately 2,400 home solar assets from a regulated utility company, with an average remaining contract life of approximately 11 years[22]. - Following the NJR Acquisition, Spruce Power's portfolio consists of 14 portfolios of home solar assets with a combined capacity of approximately 514 MWdc[24]. - The average remaining contract term for home solar assets in Spruce Power's portfolio is approximately 11 years as of December 31, 2024[34]. - Spruce Power's corporate strategy focuses on subscription-based solutions for distributed energy resources, aiming to deliver predictable revenues and profits[25]. - The company has a dedicated M&A team that has successfully acquired high-quality portfolios of solar energy systems, minimizing customer acquisition costs[30]. - Spruce Power's portfolio is geographically diverse across 18 states in the U.S., reducing exposure to localized risks and providing stable cash flows[35]. - The company aims to grow customer revenues by focusing on channels with the lowest customer acquisition costs, including acquiring existing systems and selling additional services[26]. Financial Performance - For the year ended December 31, 2024, the company's revenues totaled $82.1 million, compared to $79.9 million for the year ended December 31, 2023, reflecting a year-over-year increase of approximately 2.8%[184]. - The net loss attributable to stockholders for the year ended December 31, 2024, was $70.5 million, compared to a net loss of $65.8 million for the previous year, indicating an increase in losses of approximately 10.7%[184]. - Revenues increased by $2.2 million, or 3%, to $82.1 million in 2024 compared to 2023, primarily due to increased PPA revenues from the Tredegar Acquisition[201]. - Total operating expenses rose by $15.8 million, or 14%, to $132.5 million in 2024, driven by increased costs in operations and maintenance, selling, general and administrative expenses, and impairment of goodwill[200]. - Impairment of goodwill increased by $28.8 million, or 100%, to $28.8 million in 2024 due to a continuous decline in stock price and market capitalization[206]. - Interest income increased to $22.8 million in 2024 from $19.5 million in 2023, attributed to a full year of interest from the SEMTH Master Lease[207]. - Interest expense, net decreased by $1.7 million, or 4%, to $40.2 million in 2024, primarily due to net realized gains from interest rate swaps[208]. - Working capital as of December 31, 2024, was $76.9 million, with cash and cash equivalents totaling $109.1 million[212]. - The company had a debt balance of $705.3 million as of December 31, 2024, all of which is non-recourse project-level debt[214]. - Net cash used in continuing operating activities was $(41.7) million in 2024, compared to $(31.7) million in 2023[216]. Market and Regulatory Environment - Federal, state, and local government incentives support the adoption of solar energy, allowing Spruce Power to lower prices for customers and enhance return on investment[49]. - The Inflation Reduction Act (IRA) enacted on August 16, 2022, includes significant policy initiatives to enhance the clean energy industry, but potential revisions or delays in funding could negatively impact the company's business[50]. - The solar energy industry is still developing, and the company faces competition from traditional energy companies and other renewable energy firms, which could adversely affect its business growth[63]. - The company is subject to various risks related to regulatory changes, legal proceedings, and compliance costs, which could adversely affect business operations[61]. - Regulatory challenges in various states may limit the company's ability to deliver solar energy and qualify for incentives, impacting growth opportunities[121]. - Changes in laws regarding rebates and net metering could reduce the attractiveness of solar energy systems, affecting customer acquisition[122]. - The evolving regulatory landscape concerning electricity pricing and competition with utilities may reduce demand for the company's solar energy systems[127]. - Adverse changes in solar-related policies could negatively impact the company's financial condition and operational results[128]. Risks and Challenges - The company is exposed to risks related to the performance and reliability of solar energy systems, which could lead to warranty claims and product liability issues, adversely impacting financial performance[67]. - A material reduction in the retail price of traditional utility-generated electricity could harm the company's financial condition and results of operations[58]. - Rising interest rates could adversely affect the company's financial condition, and the effectiveness of hedging strategies may be limited[58]. - The company faces significant risks related to climate change, which could adversely affect energy production and revenue generation from solar energy systems[71]. - The company typically bears the risk of loss and maintenance costs for solar energy systems, which could lead to unforeseen expenses if repairs exceed estimates[72]. - The company may experience a reduction in the residual value of solar energy systems at the end of customer agreements, potentially impairing financial performance[73]. - Tariffs and trade restrictions imposed by the U.S. government on solar products from China could increase costs and reduce competitive pricing capabilities[75]. - The company competes with traditional energy companies and vertically integrated solar companies, which may have greater resources and market advantages[77][78]. - There is a risk of increased customer credit defaults, particularly during economic downturns, which could adversely affect revenue and financial condition[104]. - The company faces significant fluctuations in customer demand, which could affect operating results and growth potential[95]. - The company may require additional financing to support growth strategies, and failure to secure such financing could adversely affect operations[88][90]. - The company does not have direct control over supplier costs for solar energy system components, which may hinder competitive pricing[91]. - The company faces challenges in managing growth effectively, which could impact customer service and operational efficiency[86]. Management and Governance - The recent CEO transition occurred on April 12, 2024, with Christopher Hayes appointed as President and CEO, which may create uncertainty and impact business operations[98]. - Management has limited experience in operating a public company, which may hinder effective growth management and compliance with regulatory obligations[99]. - The company is subject to risks associated with proxy contests and actions of activist stockholders, which can be costly and time-consuming, potentially disrupting operations[153]. - The company has a comprehensive cybersecurity risk management program integrated into its overall enterprise risk management framework, overseen by the Audit Committee[156]. - The Audit Committee receives quarterly reports on cybersecurity matters and related risk exposures, ensuring ongoing oversight[157]. - The ability to attract and retain qualified personnel is critical, as competition for skilled employees is intense, impacting the execution of business strategies[97]. Legal and Compliance Issues - The company agreed to a settlement amount of $19.5 million to resolve class action litigation, with a net payment of $15.0 million after insurance recoveries[115]. - The SEC imposed a civil money penalty of $11.0 million for violations of federal securities laws, which has been paid[117]. - The company is currently involved in multiple legal proceedings, which could result in significant costs and resource diversion[118]. - The company faces potential patent infringement claims that could materially affect its business and financial condition[120]. - The company has received subpoenas from state attorneys general regarding its business practices, which may result in fines or penalties[131]. - The company has identified material weaknesses in internal control over financial reporting, which could lead to inaccurate financial reporting and a decline in stock price[132][133]. - The company is subject to evolving laws and regulations related to data privacy and security, which could increase operational costs and impact business[130]. Shareholder and Stock Information - The average closing price of the company's common stock was below $1.00 per share for 30 consecutive trading days in 2022 and 2023, raising the risk of delisting from the NYSE[141]. - The company has the ability to issue up to 324,696,266 shares of common stock under its 2020 Equity Incentive Plan, which could dilute existing stockholders' interests[146]. - The company has no current plans to declare cash dividends, meaning investors may need to rely on share price appreciation for future gains[139]. - Clayton Capital Appreciation Fund, L.P. and its affiliates owned approximately 2.1% of the company's outstanding shares and nominated two candidates for election as directors at the 2024 Annual Meeting of Stockholders[152]. - The company entered into a Cooperation Agreement with Clayton, agreeing to increase the Board size from six to seven directors and appoint Clara Nagy McBane to the Board[152].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from January 1, 2024 to December 31, 2024 Commission file number 001-41959 ___________________________ SolarMax ...